FDA Guidance: Plausible Mechanism Framework for Individualized Genetic Therapies

FDA Guidance Documents

Detected February 27th, 2026

Email Set alert

Summary

The FDA has issued draft guidance outlining a plausible mechanism framework for developing individualized genetic therapies. This framework provides recommendations for generating substantial evidence of effectiveness and safety for these novel treatments. The comment period for this draft guidance closes on April 27, 2026.

View original document View source feed page

What changed

The FDA has released draft guidance titled "Considerations for Use of a Plausible Mechanism Framework to Develop Individualized Therapies to Target Specific Genetic Mutations." This document describes a framework intended to help developers of individualized therapies generate sufficient clinical safety and efficacy data, along with chemistry, manufacturing, and controls (CMC) data, to support product approval or licensure. The guidance focuses on evaluating nonclinical and clinical data to demonstrate that a product is safe, effective, and manufactured to regulatory quality standards for a specific indication.

This guidance is relevant for drug and biologics developers, particularly those working on gene therapies. While it is non-binding, it outlines the FDA's current thinking on how to support approval for these complex therapies. Regulated entities should review the framework and consider submitting comments by the deadline of April 27, 2026, to influence the final version of the guidance. Failure to align with these considerations could impact the successful development and approval pathway for individualized therapies.